Background: The current study investigates the effect of transcription factor Prox1 on the proliferation, migration, and invasion ability of lung cancer.
Methods: Lung cancer cell lines (A549 and H446 cells) were transfected with Prox1NAD and siRNA, respectively. Thus, the A549 and H446 cells overexpressed Prox1 after transfection of Prox1NAD plasmids, and A549 and H446 cells have low expression of Prox1 after transfection with siRNA. Reverse transcriptase quantitative PCR and western blot analyses were used to detect Prox1 mRNA and protein expression in cells. Plate clone formation experiments and MTT experiments were used to detect cell proliferation. Western blot was used to detect the expression of Rho family-related proteins in cells.
Results: Compared to untransfected wild-type A549 and H446 that served as blank controls, the expression level of Prox1mRNA and protein in A549 and H446 cells overexpressing Prox1 after plasmid transfection was high, while the expression level of Prox1mRNA and protein in A549 and H446 cells with low expression of Prox1 after siRNA transfection was low. With the increase of Prox1 expression, the expression of RhoA and RhoC increased, while the expression of RhoB decreased.
Conclusion: The finding of this study may provide a new approach for the treatment of lung cancer using targeted gene therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218550 | PMC |
| http://dx.doi.org/10.1515/biol-2021-0056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
miR-149-3p targeting regulates the sensitivity to cisplatin to inhibit the progression of lung cancer.
Biomol Biomed
December 2024
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Article Synopsis
- Lung cancer cells often develop resistance to cisplatin (DDP), making it important to find ways to improve sensitivity to this chemotherapy drug.
- Research involving cell lines and bioinformatics identified miR-149-3p as a key regulator that can enhance the effectiveness of DDP by targeting TMPRSS4, a protein associated with cancer progression.
- Overexpressing miR-149-3p in lung cancer cells not only promoted cell death and reduced tumor growth but also increased their sensitivity to chemotherapy by downregulating TMPRSS4, revealing a potential therapeutic approach for lung cancer treatment.
The identification of noninvasive volatile biomarkers for lung cancer is a significant clinical challenge. Through in vitro studies, the recognition of altered metabolism in cell volatile organic compound (VOC) emitting profile, along with the occurrence of oncogenesis, provides insight into the biochemical pathways involved in the production and metabolism of lung cancer volatile biomarkers. In this research, for the first time, a comprehensive comparative analysis of the volatile metabolites in NSCLS cells (A549), SCLC cells (H446), lung normal cells (BEAS-2B), as well as metabolites in both the oxidative stress (OS) group and control group.
View Article and Find Full Text PDF[circDDX17 targets miR-223-3p / RIP3 to regulate the proliferation and apoptosis of non-small cell lung cancer cells].
Zhonghua Zhong Liu Za Zhi
March 2024
Department of Thoracic Surgery, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China.
To explore the molecular mechanism of circDDX17 regulating the proliferation and apoptosis of non-small cell lung cancer cells by targeting the miR-223-3p/RIP3 molecular axis. The expression levels of circDDX17, miR-223-3p, and RIP3 in human normal lung epithelial cell lines BEAS-2B and non-small cell lung cancer cells H1299, A549, and H446 were detected by reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR). The plasmids of pcDNA, pcDNA-circDDX17, anti-miR-con, anti-miR-223-3p, pcDNA-circDDX17 and miR-con, pcDNA-circDDX17 and miR-223-3p mimics were transfected into H1299 cells.
View Article and Find Full Text PDFDesign, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents.
Pharm Biol
December 2024
Translational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Context: Podophyllotoxin (PPT) derivatives, used in cancer therapy, require development toward enhanced efficacy and reduced toxicity.
Objective: This study synthesizes PPT derivatives to assess their anticancer activities.
Materials And Methods: Compounds E1-E16 antiproliferative activity was tested against four human cancer cell lines (H446, MCF-7, HeLa, A549) and two normal cell lines (L02, BEAS-2B) using the CCK-8 assay.
Mitochondrial targeting derivatives of honokiol enhanced selective antitumor activity in NCI-H446 cells and decreased in vivo toxicity in Caenorhabditis elegans.
Eur J Med Chem
January 2024
Department of Natural Product Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China. Electronic address:
Article Synopsis
- Mitochondria play crucial roles in cancer cell processes like ATP production and regulating cell death, making them important targets for cancer treatment.
- Researchers developed 28 new derivatives of honokiol, a natural compound, using special carriers that specifically target mitochondria, leading to increased effectiveness against tumor cells compared to honokiol alone.
- The most promising derivative, 2E-3-F16, showed a significant ability to selectively kill cancer cells while sparing normal cells and improved the effectiveness of cisplatin, a common chemotherapy drug, highlighting its potential as a safe and effective cancer treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!